September 16, 2020 -- AVM Biotechnology has received authorization for an investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) to evaluate its proprietary drug AVM0703 in the treatment of patients with acute respiratory distress syndrome (ARDS) mediated by COVID-19 or influenza.
AVM0703 is a proprietary formulation of high-concentration dexamethasone, which mobilizes natural killer T cells, cytotoxic T cells, and dendritic cells. The cells are highly potent against difficult-to-treat cancers and can be used to eliminate abnormal virus-infected cells, as in COVID-19 or influenza-mediated ARDS. A single dose of AVM0703 formulation of dexamethasone triggers critical immune system activation, according to the firm.
The new study will examine two populations, one with COVID-19-mediated moderate to severe ARDS and the other with influenza-mediated severe ARDS.
The drug was previously authorized for a study evaluating its effectiveness for the treatment of refractory/relapsed non-Hodgkin lymphoma.